Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $218.38M | $191.20M | $196.00M | $170.99M | $150.04M | $121.46M | $118.77M | $104.76M |
| Cost of revenue | $13.56M | $14.73M | $12.33M | $11.91M | $13.45M | $9.79M | $10.51M | $8.44M |
| Gross profit | $204.81M | $176.48M | $183.67M | $159.08M | $136.59M | $111.67M | $108.25M | $96.33M |
| Gross margin | 93.8% | 92.3% | 93.7% | 93.0% | 91.0% | 91.9% | 91.1% | 91.9% |
| Research and development | $46.23M | $52.68M | $48.79M | $40.16M | $49.54M | $44.79M | $55.01M | $45.39M |
| Selling, general and administrative | $208.14M | $185.00M | $169.30M | $150.24M | $130.28M | $120.79M | $113.27M | $95.56M |
| Operating expenses | $254.46M | $239.84M | $210.63M | $205.19M | $173.31M | $168.66M | $180.87M | $158.95M |
| Operating income | −$49.65M | −$63.36M | −$26.96M | −$46.11M | −$36.71M | −$56.98M | −$72.62M | −$62.62M |
| Operating margin | -22.7% | -33.1% | -13.8% | -27.0% | -24.5% | -46.9% | -61.1% | -59.8% |
| EBITDA | −$47.91M | −$61.67M | −$25.24M | −$44.38M | −$35.01M | −$55.26M | −$70.88M | −$60.89M |
| Interest income | $0 | −$1.19M | −$1.17M | −$1.12M | $0 | −$2.43M | −$2.21M | −$1.98M |
| Interest expense | −$1.54M | $0 | $0 | — | −$1.83M | $0 | $0 | — |
| Income before taxes | −$51.19M | −$64.54M | −$28.13M | −$47.23M | −$48.93M | −$59.41M | −$74.83M | −$64.60M |
| Income taxes | $128.00K | $0 | $430.00K | — | −$960.00K | $0 | $85.00K | — |
| Net income | −$51.31M | −$64.54M | −$28.56M | −$47.23M | −$47.97M | −$59.41M | −$74.91M | −$64.60M |
| Net margin | -23.5% | -33.8% | -14.6% | -27.6% | -32.0% | -48.9% | -63.1% | -61.7% |
| EPS, basic | −$0.99 | −$1.26 | −$0.56 | −$0.94 | −$0.97 | −$1.22 | −$1.54 | −$1.34 |
| EPS, diluted | −$0.99 | −$1.26 | −$0.56 | −$0.94 | −$0.97 | −$1.22 | −$1.54 | −$1.34 |
| Diluted shares | 51.80M | 51.20M | 50.65M | 50.02M | 49.44M | 48.87M | 48.55M | 48.14M |
Figures describe Axsome Therapeutics shares, not any token. As of Aug 10, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.